Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Backed by the Economic Development Board (EDB), the hub was launched on Nov 14 at the Lilly Digital Health and Lilly Centre ...

Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...

The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

Nevertheless, the company's lead obesity candidate ... Adam Spatacco has positions in Eli Lilly. The Motley Fool has no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 519.47% and ...

If you looked solely at its stock price, you might get the idea that Eli Lilly (NYSE: LLY) is having a bit of an off quarter.

It's shaping up to be a tough period for Eli Lilly and Company , which a week ago released some disappointing third-quarter ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Eli Lilly (LLY) has been one of the most searched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...